Mirna Therapeutics (MIRN) Halts Clinical Study of MRX34 Following Severe Adverse Events
Tweet Send to a Friend
Mirna Therapeutics, Inc. (Nasdaq: MIRN) announced its decision to close the ongoing Phase 1 study of MRX34, its investigational microRNA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
